irinotecan has been researched along with fluorodeoxyglucose f18 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Aderka, D; Davidson, T; Goshen, E; Zwas, ST | 1 |
| Sharma, RI; Smith, TA | 1 |
| Berglund, A; Byström, P; Frödin, JE; Garske, U; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A | 1 |
| Ahn, JB; Hur, H; Keum, KC; Kim, H; Kim, NK; Lee, KY; Min, BS; Yun, M | 1 |
| Bukofzer, G; Chakravartty, A; Cole, TB; Day, M; Donawho, CK; Fox, GB; Holich, KD; Luo, Y; Mudd, SR; Palma, JP; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Barrie, M; Bequet-Boucard, C; Chinot, O; Colavolpe, C; Figarella-Branger, D; Guedj, E; Mancini, J; Metellus, P; Mundler, O; Tabouret, E | 1 |
| Barot, TC; Gulec, SA; Hall, M; Pennington, K; Schwartzentruber, D; Suthar, RR; Wheeler, J | 1 |
| Hendel, HW; Jensen, BV; Nielsen, D; Skougaard, K | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Shimizu, K; Yasuda, K; Yukawa, T | 1 |
| Hendel, HW; Høgdall, EV; Jensen, BV; Johannesen, HH; Nielsen, D; Schou, JV; Skougaard, K | 1 |
| Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
| Aoyama, T; Atsumi, Y; Ju, M; Kazama, K; Numata, M; Rino, Y; Tamagawa, H; Tsuchiya, K; Yukawa, N | 1 |
1 review(s) available for irinotecan and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
4 trial(s) available for irinotecan and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals | 2009 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Denmark; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
8 other study(ies) available for irinotecan and fluorodeoxyglucose f18
| Article | Year |
|---|---|
PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Interactions; Fluorodeoxyglucose F18; Fluorouracil; Glucose; Hexokinase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals | 2008 |
18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colectomy; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Period; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; ROC Curve; Treatment Outcome | 2011 |
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Fluorodeoxyglucose F18; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
Lung cancer with sarcoid reaction in the lymph nodes following chemoradiotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Irinotecan; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiation Dosage; Radiopharmaceuticals; Sarcoidosis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[A Case of Rectal Cancer with Brain and Skin Metastasis with Long-Term Survival Managed by Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain; Capecitabine; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Positron Emission Tomography Computed Tomography; Rectal Neoplasms | 2022 |